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Abstract: Human African trypanosomiasis (HAT, or
sleeping sickness) is a protozoan parasitic infection
caused by Trypanosoma brucei rhodesiense or Trypanoso-
ma brucei gambiense. These are neglected tropical
diseases, and T.b. rhodesiense HAT is a zoonosis. We
review current knowledge on the burden of HAT in sub-
Saharan Africa, with an emphasis on the disability-
adjusted life year (DALY), data sources, and methodolog-
ical issues relating to the use of this metric for assessing
the burden of this disease. We highlight areas where data
are lacking to properly quantify the impact of these
diseases, mainly relating to quantifying under-reporting
and disability associated with infection, and challenge the
HAT research community to tackle the neglect in data
gathering to enable better evidence-based assessments of
burden using DALYs or other appropriate measures.
Introduction
Human African trypanosomiasis (HAT)—also known as
sleeping sickness—is caused by infection with one of two parasites:
Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense. These
organisms are extra-cellular protozoan parasites that are trans-
mitted by insect vectors in the genus Glossina (tsetse flies). As with a
few other human pathogens (e.g., tuberculosis caused by
Myobacterium tuberculosis and M. bovis), HAT shares the confusion
that two different causative organisms cause a similar clinical
disease. The parasites can be distinguished through molecular
methods [1,2], but not parasitologically; the geographic range of
the parasites has been a key component of the differential
diagnosis of HAT, as T.b. gambiense occurs in West and Central
Africa, and T.b. rhodesiense occurs only in East Africa, though there
are concerns that an overlap may now have occurred in their
ranges [3]. To understand the epidemiology of HAT, as well as its
disease and economic burden, it is essential to understand the
distinction between the diseases caused by the two parasites.
HAT is restricted to sub-Saharan Africa, in the range of the
tsetse vector. The distributions of tsetse (possibly more than 30
species [4] with affinities for specific habitats, although not all
species have been confirmed as parasite vectors), and of the
parasites within the vector range, are both focal. Thus, HAT is a
public health problem where the vector, the parasite (and its
reservoir hosts), and humans co-exist.
Here, we review what we know—and, importantly, what we
don’t know—about the burden of HAT in sub-Saharan Africa,
with an emphasis on data sources and methodological issues
relating to the use of the disability-adjusted life year (DALY) as a
metric for assessing the burden of this disease.
What We Know about HAT Epidemiology and
Burden
T.b. rhodesiense isazoonosis[5,6],withanumberofwildlife[7]and
domestic animal species known to act as reservoirs. Where wildlife is
not abundant, domestic species, particularly cattle, are the main
reservoir [8], with livestock demography driving outbreaks [9]. T.b.
gambiense is generally not considered zoonotic—it can be isolated
from animal hosts [10,11], but large-scale control campaigns
targeting only the human reservoir (active screening and treatment
of human cases) are able to locally eliminate transmission [12,13],
and theoretical assessments of control options [14] confirm that from
an epidemiological perspective, the presence of animal hosts is
unlikely to mean they serve as a reservoir of infection for humans
[15] (such hosts and their potential as a source for re-introduction of
the parasite to the human population would need to be considered if
ever aiming for total elimination of the disease, however). The
transmission of HAT occurs primarily in rural areas (with a few
exceptions, including peri-urban Kinshasa [16]), in areas at the
furthest extremities of the formal health system, creating particular
problems for patients to access health care [17,18], for control
campaigns to have an effective outreach [19], and, importantly, in
the assessment of the burden of infections, hindering efforts to collect
data on how many people are at risk, how many people are infected,
and what the impact of the disease is on the social environment.
These are not issues restricted to HAT (of either form), but are
general among many ofthe neglected tropical diseases and neglected
zoonotic diseases [20,21].
The available estimates for HAT indicate that 60 million people
are at risk (both forms combined) in sub-Saharan Africa [22]
(though the evidence base for this figure is questionable and is
currently being revised; see http://www.who.int/trypanosomiasi-
s_african/country/en/) in approximately 250 distinct foci (see
Figure 1) (a focus is loosely defined as ‘‘a zone of transmission to
which a geographical name is given’’ [22]). The greatest burden of
reported cases is due to T.b. gambiense, with 23,832, 19,901, 17,036,
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T.b. rhodesiense cases in 2002, 2003, 2004, 2005, and 2006,
respectively [23,24]. Approximately two-thirds of reported T.b.
gambiense cases occur in the Democratic Republic of Congo (DRC)
[23]. These data, especially for T.b. gambiense, illustrate an
encouraging trend for countries where concerted efforts have
been mounted (mainly Angola, DRC, and Sudan) to control HAT,
and the decrease in incidence in recent years is due in large part to
enormous efforts involving active case detection; these efforts need
to be maintained despite the increasing cost per patient of
detecting additional cases in control programmes that are
successful [25]. There is much still to do before elimination of
HAT can be considered a real option in the medium-term future.
It has been estimated that up to 70,000 [24] cases actually occur
annually (including un-reported cases); a previous estimate was
300,000 [22]; the disparities in these estimates illustrate the need
for formal methods to quantify the substantial hidden burden of
HAT (see below).
HAT, without distinction between T.b. gambiense and T.b.
rhodesiense, was considered in the first Global Burden of Disease
assessments [26], and estimated to result in 1.78 million DALYs
lost across Africa, using a standard West 26 life table (life tables
describe age-specific mortality in a population and determine, for
example, the number of years of life lost following death at a given
age), a disability weight per episode of 0.35 [27], and an annual
incidence of 32,000 reported cases, including 24,000 deaths [28].
Subsequent iterations of the DALY provided revised estimates—
e.g.,1.34 million DALYs lost to HAT in 2000 [29] and 1.54
million DALYs lost in 2002 [30], using an average disability-
weight of 0.191 [31] and 48,511 deaths. The relative ranking of
HAT to other conditions from the 2000 DALY estimates are
shown in Table 1. The justification for many of the parameters
pertaining to HAT and used in the Global Burden assessments
(e.g., disability weighting, estimates of incidence) are not
transparent and have not been published.
Issues in Assessing the Burden of HAT
Quantifying the impact of a disease—its burden—is a necessity
in providing an evidence base for effective decision making in
relation to planning of control and interventions [32]. Burden can
be measured in terms of impact at a range of scales—the
individual, family groups, society at large. For decision-making at
the societal level (e.g., government policy, national or regional
budgetary allocation, etc.), a societal, or population-based
approach, is most appropriate. For this, a range of tools are
available [33,34]; the DALY is a useful and now well-established
measure [35–37]. Proper quantification matters greatly to the
neglected diseases, because a primary reason for their neglect is
that their true impact on society is not known. For focal diseases
such as HAT, it is necessary to choose an appropriate scale at
which the assessment of burden is carried out—in many sub-
Saharan African countries, the national level burden of malaria,
for example, will exceed, by orders of magnitude, that of HAT,
leishmaniasis [38], cysticercosis [39], or many other neglected
infections. However, within a province or district, where
transmission of a neglected disease occurs, it may assume a much
greater importance; as budgetary decisions are increasingly made
Figure 1. Map of Sleeping Sickness. Image credit: [23].
doi:10.1371/journal.pntd.0000333.g001
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measure the burden of disease at this level [42,43]. Scientific
research at a range of geographic scales that uses recognised health
metrics as an outcome can therefore assist in the development of
effective policy.
While it is important to determine disease burden at a range of
temporal and spatial scales, there are some pitfalls in doing so; at
small (e.g., local) scales, annual stochastic variations in burden,
resulting from annual variations in incidence, may be large and
care should be taken not to over-interpret them. Also, HAT not
only occurs focally, but occurs in both endemic and epidemic
situations. While relative disease burdens during periods of
endemic and epidemic periods matter in themselves, it would be
a mistake to calculate a DALY for an epidemic and assume that
this was then the more general baseline level of burden for longer-
term planning. Rather, when determined for epidemics or
outbreaks (e.g., [44]), this should be explicit. Routine data
collection during periods of endemic transmission may be lacking
in many settings, while epidemics or outbreaks focus attention on a
disease, resulting in greater availability of data [45,46]. Epidemic
situations do, however, present a particular set of conditions for
the assessment of the cost-effectiveness of control/long-term
investment [47,48], and DALYs, as an outcome measure of such
analyses, can add significantly to the valuation of alternate
investment options. The time units chosen for burden assessments
also matter, particularly if outputs influence resource allocation.
Recent decreases in the number of reported HAT cases [23]
could, for example, lead to a reduction in effort in detecting future
cases, a situation which has previously led to disease resurgence
[49,50]. It becomes important that temporal trends in incidence
are accounted for in the choice of time period for assessing burden,
though the sporadic nature of data availability may make this
difficult in practice.
Other issues arise with regional and local studies; when
conducting evaluations of disease burden within a region (e.g.,
relative burdenof malaria and HATinEast Africa),it isappropriate
touselife tables thatrelatetothe population understudy[27,51,52].
Indeed, country-specific life tables are produced by WHO (see
http://www.who.int/whosis/database/life_tables/life_tables.cfm).
However, doing so restricts the comparability of estimates between
sites [53]; thus, global DALY estimates are produced using the West
26 Model Life Table [27]. For HAT, which exists only in sub-
Saharan Africa, this is less of a problem, and for regional studies,
using regional life tables may be more appropriate as doing so does
not over-estimate burden in these communities [54]. To address
these issues, a concerted research effort is required to carry out finer
scale studies in a range of HAT foci that be justifiably generalised to
HAT transmission zones as a whole.
Economic Burden of HAT
Wedo not aim to provide a thorough review ofeconomic studiesof
HAT; however, while DALYs, and other measures, in themselves
allow adverse health outcomes to be rated against each other, a more
practical (and intended) use of such measures is as an outcome in cost-
effectiveness analyses [51,55] (in terms of, for example, dollars spent
perDALYsaverted).Wemustask,therefore,howcost-effectiveitisto
controland treatHAT.Usefulinthiscontextistheruleofthumbthat
a cost of US$150 per DALY averted and US$25 per DALY averted
is ‘‘attractive’’ and ‘‘highly attractive’’, respectively [56]. Unsurpris-
ingly, studies are few and far between for HAT, and have tended to
focus on T.b. gambiense. DALYs have been used as an outcome
measure in analysing the cost-effectiveness of treatment options for
gambiense HAT [57]. Shaw and Cattand [25] illustrate that above a
prevalence of approximately 2%, it becomes highly attractive to
screen for and treat gambiense HAT using mobile teams carrying out
active surveillance (the use of mobile teams is reviewed elsewhere
[58,59]). At lower prevalences, active screening may not be cost-
effective in the short term, emphasising that control efforts for this
disease must take a long-term perspective. Others conclude that
mobile teams have too poor a coverage compared to well-trained
community health workers [60]. Lutumba et al. [61] quantified the
cost-effectiveness of control activities in terms of DALYs averted in
Buma (Democratic Republic of Congo), a T.b. gambiense focus. In a
population of 1,300, an active case finding activity resulted in 1,408
DALYs averted, for a cost of US$17 per DALY averted.
For T.b. rhodesiense, hospital-based interventions alone have been
shown to be cost-effective for HAT control in rural settings in
Uganda, with a mean cost per DALY averted (for reported cases) of
US$8.50 [44]. Compared to hospital-based treatment of many other
infections (e.g., cutaneous leishmaniasis in Colombia [48], where the
cost per averted DALY was in the region of US$15,000), this is highly
cost-effective. Such calculations do not generally include indirect costs
to the household, which have been considered in a few studies and
found to be substantial [17,18,61]. Devising effective methods to
maximise hospital attendance and reduce the number of unreported
cases in the community should thus be a priority.
The economic burden of livestock trypanosomiasis has also
been reviewed [62–64]; for a range of neglected zoonoses,
applying treatments to the animal reservoir specifically as a public
health measure has been shown to be cost-effective [65], with great
added benefits when these integrated interventions also improve
animal health and productivity. Currently, a large-scale cattle-
targeted intervention is being implemented in Uganda [66] to
control the spread of T.b. rhodesiense. Quantifying the dual burden
of infections to livestock and humans, and the added benefits to
both when control is implemented, is an under-researched area
and requires novel metrics and systematic data gathering across
the range of neglected zoonotic diseases [65].
Disability
DALYs consist of two major, additive components: a metric for
summing mortality in a population, Years of Life Lost due to death
Table 1. Selected DALYs Lost by Cause, 2000.
Cause DALYs Lost
HIV/AIDS 64,970,667
Malaria 39,568,398
Lymphatic filariasis 4,576,994
Trachoma 2,559,951
Leishmaniasis 1,752,384
Schistosomiasis 1,485,408
Ascariasis 1,405,795
HAT (trypanosomiasis) 1,335,075
Trichuriasis 803,111
Japanese encephalitis 604,002
Chagas disease 574,644
Dengue 542,954
Onchocerciasis 427,440
Leprosy 188,542
Hookworm disease 64,048
Data from [97].
doi:10.1371/journal.pntd.0000333.t001
www.plosntds.org 3 December 2008 | Volume 2 | Issue 12 | e333with a condition (YLL), and a metric for summing morbidity in a
population, Years of Life Lived with a Disability from a condition
(YLD). The important component of YLDs is the disability
weighting associated with a condition; the sum of time spent in a
condition for each age group in a population is multiplied by this
weighting to determine the scale of morbidity due to the condition
in that population. Ideally, this is done for each of the components
of morbidity—the sequelae—associated with the disease. Thus, for
Chagas disease (due to infection with Trypanosoma cruzi), YLDs are
made up of episodes plus specific sequelae relating to the incidence
of cardiac complications resulting from infection, each of which
has a disability weighting and an estimate for duration.
Up to the present, a weighting of 0.35 [27] and later 0.191 [67]
have been used for HAT, irrespective of whether T.b. gambiense or
T.b. rhodesiense HAT are being considered. No sequelae are
formally listed in the disease definition for HAT used for DALY
inputs [28], with the unit of measure being an episode (case
definition: ‘‘Infection with protozoa of the genus Trypanosoma,
excluding T. cruzi’’ [68]), with a standard duration of 5 years per
episode (this has been recently revised for the 2004 Global Burden
of Disease revision such that the length of a T.b. gambiense episode is
5 years and T.b. rhodesiense 1 year duration (C. Mathers, personal
communication), recognizing that the clinical syndromes associat-
ed with infection with the different parasites have very different
durations [69]). While broad differences between T.b. gambiense
and T.b. rhodesiense have thus been accounted for, DALY estimates
for HAT have not attempted to account for sequelae [70–76]. A
range of sequelae should be considered for infection with both
parasites—see Box 1 and Text S1—although data are lacking to
enable estimates of the incidence of these sequelae to be
extrapolated to the affected population at large. The stage of
disease should equally be distinguished [44]: in the absence of
treatment, both T.b. gambiense and T.b. rhodesiense have an early and
late stage. The early stage is a febrile illness, while the second stage
is defined by cerebrospinal fluid parameters—an elevated
leukocyte count (.5 cells/mm
3) or high protein levels (.37 mg/
100 ml) or parasites in the cerebrospinal fluid [22,77]. Late stage
disease is neurological [78], culminating in coma and death in the
absence of treatment.
Morbidity induced by treating HAT has also not been taken in
to account in burden calculations: the drugs to treat HAT are
generally toxic [79,80], with a relatively high proportion of side
effects (e.g., exfoliative dermatitis in 1% of treatments with
suramin [see Figure 2]; melarsoprol-induced encephalopathy in
5%–10% of patients). For other diseases, morbidity resulting from
treatment has been included in burden estimates, e.g., vaccine
reactions account for approximately 2.5% of the overall DALY
score for rabies in Asia and Africa [81]. There is also some
evidence of long-term impacts of T.b. gambiense HAT infection
beyond parasitological cure [82,83], but the significance of this at
a population level remains to be quantified by the HAT research
community, and there are no similar studies for T.b. rhodesiense.
Under-Reporting
A significant limitation of incidence figures, and subsequent
estimates of burden based on these, published through the World
Health Organization [24] and originating from national bodies
(e.g., ministries of health), is that they relate only to reported
deaths. HAT cases are itemised when they are identified in
community screening exercises (active detection) or passively in
Box 1. Summary of Sequelae Associated with HAT; see Text S1 for More Details.
Early stage Non-specific signs that can include skin lesions, chancre, pruritus, and cardiac, endocrine, and gastroin-
testinal problems.
Late stage
(parasite infection
of the central
nervous system)
Tremors, motor weakness, walking difficulties, sensory disorders, visual impairments, headache, sleep
disturbances that deteriorate into coma.
Early stage
treatment
Suramin: Reactions depend on overall patient condition, with severe reactions in ,5% of patients, and
include pyrexia and mild nephrotoxicity, kidney damage, collapse with nausea, vomiting, shock, delayed
hypersensitivity reactions (e.g., exfoliative dermatitis), severe diarrhoea, and jaundice.
Pentamidine: Hypotensive reactions, and damage to liver, kidneys, and the pancreas.
Late stage
treatment
Encephalopathy occurs in 5%–10% of treated cases, with a mortality rate of 10%–70%. Convulsions,
progressive coma, or psychotic reactions. Acute haemorrhagic leuco-encephalopathy associated with
progressive coma and hypoxic brain damage with convulsions or heart failure. Other effects of
melarsoprol include liver toxicity, severe enterocolitis, fatigue, arthralgia, myalgia and fever, pruritus,
urticaria, and gastrointestinal reactions; cardiovascular side effects such as tachycardia, palpitations,
chest pain, hypotension, and phlebitis were reported.
A relapse rate of 3%–10% is commonly reported; however, high failure rates have been reported
recently from T.b. gambiense areas of some countries.
Eflornithine treatment frequently results in side effects, although they are less severe than melarsoprol-
induced encephalopathy, and usually reversible. Reactions include convulsions, gastrointestinal
symptoms, bone marrow toxicity resulting in anaemia, leucopenia and thrombocytopenia and
alopecia, fatigue, arthalgia, dizziness, insomnia, fever, headache, and anorexia.
Long-term
sequelae beyond
cure
Few data, with confounding between impacts of infection and treatment. Possible growth retardation
and neurological impairment.
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non-hospitalised HAT cases are not recorded, and patients are
often unable to afford to present for treatment [18]. For T.b.
rhodesiense, studies based on quantifying under-reporting using data
on the early:late stage ratio [85] have shown that between 38%
and 41% of T.b. rhodesiense cases go un-reported [85,86] in
Uganda, with a similar picture in Tanzania (L. Matemba,personal
communication). For T.b. gambiense, there have been preliminary
attempts to estimate this directly [61]; Robays et al. [59] used a
Piot modelling approach and highlighted that many cases may be
missed during active screening programmes for T.b. gambiense
(partly due to test sensitivity); cases will, of course, also be missed
where there are no case-detection programmes on-going, and
clearly, cases will be missed where active detection activities are
not on-going. . Un-reported cases go untreated and almost
invariably result in death. Existing estimates of under-reporting
need to be validated in a range of settings before they can be
confidently extrapolated, however, as there may be site-specific
influences on the magnitude of this parameter. With few
exceptions (e.g., leishmaniasis [87], T.b. rhodesiense HAT [85],
rabies [81,88]), under-reporting rates have rarely been properly
quantified for neglected diseases, so progress in this regard for
HAT is promising. Unfortunately, health care systems themselves
may even be missing many cases of HAT on presentation at non-
specialist units [17], while in some settings communities may be
aware of the disease and its dangers but not report cases, as they
are aware that drugs and treatment are not available in health
units [89]. A greater research effort is required to investigate the
impact of these factors on reporting rates in different parts of
Africa, and this research needs to translate to activities to remedy
the situation at country and local levels. Across the continent, we
have seen that a figure of 70,000 cases per year is cited; if this is
even roughly accurate, it recognises that approximately 50,000
HAT cases may be undetected, and thus die (unaccounted for in
the burden calculations), in any given year.
Challenges and Future Steps
Akin to the challenges involved in the assessment of burden of
most neglected tropical diseases, data on HAT incidence,
morbidity, and mortality is incomplete and fragmented at present.
Under-reporting of HAT, exacerbated by insufficient access to
health care by patients, as well as confounding with concurrent
endemic diseases such as malaria and HIV/AIDS, is a significant
obstacle. Methods to quantify levels of under-reporting of both
T.b. gambiense and T.b. rhodesiense [59,85] need to be validated and
extended to foci in different countries. As well as estimating
mortality, those living in HAT foci must be enumerated to provide
a denominator for incidence figures; estimates of the population at
risk, validated by field data, are urgently required. This would
enable the limited resources available for data collection and
public health interventions to be deployed as efficiently as possible.
We have seen that morbidity associated with HAT is currently
represented by single, average disability weightings in global
comparative assessments. This does not reflect the dual causation
of HAT (gambiense and rhodesiense), the distinction between early and
late stages (and the reduction in the societal burden that can be
achieved by early detection of cases), or treatment-associated
morbidity. While alternative disability weightings for use in DALY
calculations have been proposed and used [44], a wider
consultative exercise is necessary to reach a data-driven consensus.
This review has largely concentrated on the DALY as a metric
for assessing the burden of HAT. There have been many criticisms
of this measure [90,91], and its value in assessing the burden of
neglected diseases specifically has recently been questioned
[20,92]. Other measures that correct issues in the DALY metric
should be developed, but for the short to medium term, the DALY
is firmly in place as the metric of choice, with a range of
refinements, particularly in terms of transparency of inputs,
planned for the next iteration of the Global Burden of Disease
project [31]. Importantly for HAT and other neglected diseases,
simply changing the metric will not address the core issues:
tackling neglect in relation to understanding disease epidemiology,
at a range of spatial scales, including collecting data to make better
decisions about control and provide material for advocacy. Who is
Figure 2. Child with Resolved Exfoliative Dermatitis (Epidermal
Necrolysis) Resulting from Early Stage T.b. rhodesiense HAT
Treatment with Suramin. The acute stage of this condition presents
with blistering and the peeling off of large areas of skin; complications
due to secondary infection are likely. Image credit: Eric Fe `vre.
doi:10.1371/journal.pntd.0000333.g002
Box 2. Key Learning Points
1. HAT is a neglected tropical disease with two causative
organisms, Trypanosoma brucei rhodesiense and T.b.
gambiense; the burden of HAT must account separately
for infection with these two parasites.
2. The true burden of HAT is poorly reflected in many
existing assessments, as is the case with other neglected
diseases.
3. HAT burden assessments need to account for parasite-
specific, disease stage–specific, and treatment-related
morbidity.
4. The rate of HAT under-reporting is as high as 40% in
some T.b. rhodesiense foci; under-reporting has not been
formally quantified for T.b. gambiense.
5. The population at risk from HAT needs to be quantified
to serve as a denominator for incidence calculations.
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they suffer? How many people die with un-diagnosed infection?
What co-factors impact on the burden of infection and what co-
morbidities [93] does HAT share with other, concurrent
infections? Will it be cost-effective to deploy novel therapies
[94]? These are not new questions, but contemporary answers are
lacking. Importantly, answering them is a fundamental first step in
the proper assessment of the burden of disease and in providing an
evidence base for measuring the success of existing and future
HAT control initiatives. Existing databases should be mined to
extract data that helps answer these questions, and funding must
be made available to address these issues appropriately where data
do not already exist. The HAT research community appears to
have mobilised to address the neglect in the development of
therapeutics for the disease [95,96], and must take up the equally
important challenge of better understanding the impact of this
infection in affected populations.
Supporting Information
Text S1 Online Appendix: Sequelae
Found at: doi:10.1371/journal.pntd.0000333.s001 (0.04 MB PDF)
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